Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/jcm10091919
Keywords
myeloid-derived suppressor cells (MDSCs); immune checkpoint inhibitors (ICIs); haematological malignancies; immune resistance
Categories
Ask authors/readers for more resources
Myeloid-derived suppressor cells (MDSCs) are immature myeloid lineage cells that have been associated with tumor processes, including resistance to immunotherapy. Current research suggests that MDSCs, in combination with immune checkpoint inhibitors (ICIs), may be used to treat various hematological neoplasms.
Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available